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Mankin� is at risk �f l�sin� the fi�ht a�ainst infecti�us �isease,� as the 
success �f antibi�tics fa�es an� �e’re still ill-�re�are� f�r ne� viral 
�an�emics. Michael Gross re��rts. Fighting disease: In the first �eca�es after 
the intr��ucti�n �f antibi�tics,� there �as 
�i�es�rea� ��timism that the fi�ht a�ainst 
infecti�us �isease c�ul� be ��n. This early 
a�vert f�r �enicillin �as tar�ete� at W�rl� 
War II servicemen. (Picture: Wiki�e�ia.)F�r a fe� �eca�es,� ar�un� the 
mi��le �f the 20th century,� there �as 
�i�es�rea� ��timism that science 
c�ul� �in the fi�ht a�ainst infecti�us 
�iseases,� re�uce their s�rea� an� 
the �ama�e they �� t� the infecte�,� 
an� even era�icate s�me. Penicillin 
became available in the 1940s an�,� 
in the �eca�es after that,� m�re an� 
m�re antibi�tics �ere �evel��e� 
an� successfully use� in the fi�ht 
a�ainst �isease. On a se�arate 
fr�nt,� the successful era�icati�n 
�f small��x thr�u�h vaccinati�n 
sh��e� that �isease threats can be 
eliminate�. H��ever,� by the en� �f 
the 20th century,� small��x remaine� 
the �nly exam�le �f era�icati�n,� ne� 
�ath��ens emer�e�,� an� many �l� 
f�es,� such as tubercul�sis,� sa� a 
resur�ence.
Furtherm�re,� scientists f�un� 
that bacterial �ath��ens �evel�� 
resistance a�ainst existin� 
antibi�tics as fast as the �harma 
in�ustry can �evel�� ne� �nes. 
This threat �i�n’t arise entirely fr�m 
natural causes. It became clear in the 
1990s that the �i�es�rea� misuse 
an� �veruse �f antibi�tics,� such 
as their blanket use in a�riculture,� 
create� the envir�nments �here 
micr�bial strains are enc�ura�e� t� 
�ass ar�un� existin� resistance traits 
an� even t� �evel�� ne� �nes. 
F�r a �hile,� the in�ustry trie� t� 
kee� u� the race an� �evel��e� ne� 
antibi�tics,� but in recent years,� the 
�i�eline �rie� u�. As Laura Pi���ck 
fr�m the Antimicr�bial A�ents 
Research Gr�u� at the University 
�f Birmin�ham ��inte� �ut in a 
c�mment f�r The Lancet last year,� n� 
m�re than three antibacterial a�ents 
�ere a��r�ve� since 2008,� c�m�are� 
�ith 16 in the years 1983 t� 1987. 
Pi���ck lists several reas�ns f�r 
this �ecline in �ru� �evel��ment: 
“mer�ers bet�een �harmaceutical 
c�m�anies have re�uce� the number 
an� �iversity �f �ru�-�isc�very 
teams,� an� many c�m�anies have 
�ith�ra�n fr�m �evel��ment �f 
antibacterial �ru�s” she �rites. She als� ��ints �ut that initial h��es 
f�r �en�mics t� yiel� ne� tar�ets 
f�r antibacterial �ru�s have been 
�isa���inte�. Finally,� she ��ints 
�ut that f�r c�m�anies �evel��in� 
antibi�tics “the return �n investment 
is l�� because antibi�tics,� unlike 
many �ru�s,� are usually use� f�r 
sh�rt-term c�urses �f treatment 
(5–7 �ays).” T� im�r�ve the ec�n�mic 
viability �f such �ru�s she su��ests 
they mi�ht be s�l� at hi�her �rices,� 
es�ecially c�nsi�erin� the years �f 
life they save in c�m�aris�n t� m�re 
ex�ensive but less efficient cancer 
�ru�s. Alternatively,� ��vernments 
an� aca�emic instituti�ns c�ul� 
take u� m�re �f the research an� 
�evel��ment ��rk. 
“This is the �ara��x �e fin� 
�urselves in,�” says Pi���ck,� “at the 
very time �e have the kn��le��e t� 
�esi�n ne� an� effective antibi�tics,� 
fe� �harmaceutical c�m�anies �ish 
t� �evel�� them. In all likelih���,� 
�isc�very an� early research �ill be 
by aca�emic researchers an� clinical 
research an� �evel��ment by the 
c�mmercial sect�r. T� �et this m��el 
��rkin� effectively t� meet the 
bacterial infecti�n challen�es,� a ne� 
fun�in� m��el is require�.” 
What �as �nce the sin�le bi��est 
bacterial threat in in�ustrialise� 
c�untries,� the methicillin-resistant 
strains �f Staphylococcus aureus 
(MRSA),� seems t� have subsi�e� 
s�me�hat in the last fe� years. In 
2011,� the number �f rec�r�e� cases 
�f MRSA infecti�ns fell t� a rec�r� 
l��. This si�nificant success is the 
result �f the attenti�n hea�e� �n 
MRSA an� similar Gram-��sitive 
bacteria �n all levels fr�m �ru� 
�evel��ment thr�u�h t� clinical 
�ractice. But in the meantime,� 
Pi���ck �ia�n�ses,� there is a 
“�enuine rarity �f a�ents t� treat 
infecti�ns cause� by Gram-ne�ative 
bacteria.” 
Gram-ne�ative bacteria inclu�e 
E. coli an� the �neum�nia �ath��en 
Klebsiella pneumoniae. Resistance 
traits kn��n as NDM-1 an� KPC,� res�ectively,� make these bacteria 
resistant t� carba�enem antibi�tics 
an� c�ul� bec�me a threat in 
the future. As the �utbreak �f a 
�ath��enic E. coli strain in Germany 
in June 2011 has �em�nstrate� �nce 
m�re,� �an�er�us infecti�ns can 
c�me a��arently �ut �f n��here an� 
�reak hav�c even bef�re the me�ical 
ex�erts are able t� ��rk �ut �hat is 
��in� �n. 
The British S�ciety f�r 
Antimicr�bial Chem�thera�y has 
recently launche� a �l�bal initiative 
calle� Antibi�tic Acti�n (htt�://
antibi�tic-acti�n.c�m/),� �hich aims 
at “Inf�rmin� all ab�ut the nee� 
f�r �isc�very,� �evel��ment an� 
a��r��riate use �f antibi�tic a�ents.”
Alternatives to antibiotics
With hin�si�ht,� �ne mi�ht ar�ue that 
antibi�tics,� �ri�inally �evel��e� by 
fun�i,� �ere never ��in� t� �i�e �ut 
bacterial threats. After all,� bacteria 
have c�existe� �ith antibi�tic-
�r��ucin� fun�i f�r hun�re�s �f 
milli�ns �f years an� survive� 
by �evel��in� suitable �efence 
mechanisms. An� �ith a �enerati�n 
s�an that may be as sh�rt as 30 
minutes,� bacteria can ev�lve very 
quickly. In an attem�t t� by�ass 
the arms race bet�een antibi�tics 
�r��ucers an� their micr�bial 
tar�ets,� researchers are n�� 










Achilles heel: Bacterial �ath��ens �ften   
 �e�en� �n �ili f�r their attachment t� h�st 
 tissues. Researchers are l��kin� f�r ne� 
�ru� can�i�ates that can interfere �ith the 
 c�m�lex self-assembly �f these �r�tein fibres 
at a s�ecialise� ��re c�m�lex (usher) in the 
�uter membrane (OM). Cha�er�nes in the 
�eri�lasm (P) �r�tect the in�ivi�ual buil�in� 
bl�cks fr�m a��re�ati�n. (A�a�te� fr�m 
Remaut et al. (2008),� Cell  133,� 640–652.)
Fire bird: In��nesian s�l�iers in �r�tective cl�sin� thr�� a slau�htere� chicken int� fire �urin� 
a j�int bir� flu �reventi�n �rill carrie� �ut in Jakarta,� In��nesia,� in 2008. In��nesia has rec�r�e� 
m�re than 100 human �eaths fr�m bir� flu since 2003. (Ph�t�: AP Ph�t�/Ir�in Fe�riansyah.)Firstly,� alth�u�h �en�mics has 
faile� t� �r�vi�e ne� miracle cures 
f�r infecti�us �iseases,� it may still 
save the �ay in c�mbinati�n �ith 
existin� �ru�s. If an� �hen �en�mic 
analysis at the ��int �f care bec�mes 
a r�utine �r�ce�ure,� ��ct�rs c�ul� 
establish the �recise nature �f a 
bacterial infecti�n inclu�in� the 
�resence �f any resistance traits. 
This ��ul� all�� them t� a��ly 
existin� �ru�s much m�re selectively 
an� efficiently. It ��ul� als� im�r�ve 
the c�st efficiency �f clinical trials 
f�r ne� antimicr�bial a�ents,� 
as �ne c�ul� select trial �r�u�s 
�ith infecti�ns fr�m a s�ecific,� 
�ell-�efine� �ath��en. 
It may als� be a ���� i�ea t� a��ly
�ru�s that ��n’t kill bacteria but �nly 
su��ress �ath��enic traits such 
as t�xin secreti�n �r c�l�nisati�n 
�f their h�st. The fun�amental 
�ifference is that a �ru� that st��s,� 
f�r instance,� E. coli fr�m attachin� 
t� the human urinary tract �ith�ut killin� the bacteria ��esn’t exert as 
much �f a selective �ressure as an 
antibi�tic that ��ses an a�a�t-�r-�ie 
threat t� the micr�bes,� an� theref�re 
��ul�n’t carry nearly as bi� a risk �f 
resistance �r�blems. Furtherm�re,� 
a��r�aches that �nly �isarm the 
�ath��en are less likely t� affect the 
‘frien�ly’ bacteria in �ur intestines,� 
ex�erts believe.
One �r�misin� tar�et �f such 
alternative antimicr�bials is the 
assembly �f the �ili,� the ‘hairs’ that 
all�� bacteria t� bin� t� e�ithelia 
�f infecte� h�sts,� like E. coli ��es 
in urinary tract infecti�ns. Pili are 
self-assemblin� chains �f �r�tein 
subunits,� an� the mechanisms �f their  
assembly have been eluci�ate� in 
s�me �etail in recent years (Remaut 
et al. (2008),� Cell 133,� 640–652). The 
research �r�u� �f Fre�rik Almqvist 
at the University �f Umeå,� S�e�en,� 
has alrea�y synthesise� an� starte� 
testin� a number �f synthetic 
chemicals �evel��e� �ith the aim �f 
interferin� �ith the assembly �f �ili. 
A recent structure-activity survey 
fr�m the �r�u� has in�ee� reveale� 
s�me �r�misin� �ru� can�i�ates 
(E. Ch�rell et al. (2012),� Bi��r�. Me�. 
Chem. htt�://�x.��i.�r�/10.1016/
j.bmc.2012.01.048). 
Researchers are als� tar�etin� 
the secreti�n systems that enable 
�ath��enic bacteria t� exu�e their 
t�xins,� �hich are �ften the main 
cause �f the harm that the �ath��ens ��. The �r�u� �f Richar� Pickers�ill 
at Queen Mary,� University �f L�n��n,� 
has recently re��rte� �r��ress in the 
structural an� functi�nal stu�ies �f 
the ty�e II secreti�n system,� �hich 
is active in Vibrio cholerae as �ell 
as in �ath��enic strains �f E. coli 
(PL�S Path��. (2012) 8,� e1002531. 
��i:10.1371/j�urnal.��at.1002531).
An�ther alternative that has 
ex�erience� a renaissance �f s�rts 
in recent years is the thera�eutic use 
�f bacteri��ha�es (Curr. Bi�l. (2011),� 
21,� R267–R270). One si�nificant 
issue there is �hether the use �f 
mixtures �f �ha�es,� kn��n as �ha�e 
c�cktails,� is m�re efficient than that 
�f s�ecific sin�le s�ecies �f �ha�es. 
“The ��tential ��rry in terms �f 
usin� �ha�e c�cktails is that they 
select f�r bacteria that are n�t �nly 
m�re resistant t� the �ha�es use� in 
the treatment,� but als� ne� �ha�es 
that they have n�t ex�erience�. In 
�ther ��r�s,� the c�cktail treatment 
mi�ht,� in fact,� select f�r a �eneral 
resistance mechanism,� makin� 
future treatment less effective,�” 
ex�lains Britt K�skella fr�m the 
University �f Exeter,� UK. “We teste� 
this i�ea usin� �ha�es that infect 
the �lant �ath��en,� Pseudomonas 
syringae �f t�mat�,� an� f�un� that 
usin� a c�cktail �i� n�t hin�er 
the ev�luti�n �f resistance. The 
���� ne�s is that,� at least f�r the 
�ha�e c�mbinati�ns �e use�,� the 
c�cktail �i� n�t select f�r increase� 
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Infectious agent: C�l�ure� transmissi�n electr�n micr��ra�h (TEM) �f a sin�le Beijin� influenza 
virus. The virus c�nsists �f a c�re �f RNA (re�) surr�un�e� by a s�ike� �r�tein envel��e �f 
haema��lutinin (br��n). The s�ikes a�here t� h�st cells �urin� infecti�n. (Ph�t�: Science 
Ph�t� Library.)resistance a�ainst future �ha�es,�” 
K�skella says. S� c�mbinin� �ha�es 
in a c�cktail treatment seems t� �� 
neither harm n�r ���� (Pr�c. R. S�c. 
B (2011),� ��i:10.1098/rs�b.2011.2259). 
H��ever,� her research als� f�un� 
that the c�st �f a�a�tin� t� multi�le 
�ha�es re�uces the fitness �f the 
survivin� bacterial strains,� c�m�are� 
�ith th�se that �nly ha� t� c��e �ith 
a sin�le �ha�e s�ecies. 
Researchers have als� h��e� that 
antimicr�bial �e�ti�es �f the ty�e 
that �as first �isc�vere� in fr�� skin 
in the 1980s mi�ht be �evel��e� 
int� antimicr�bial �ru�s t� ste� in 
f�r tra�iti�nal antibi�tics. A recent 
fin�in� fr�m the �r�u� �f Michael 
Br�ckhurst at the University �f 
Liver���l,� h��ever,� may �eflate this 
h��e. The researchers f�un� that 
Staphylococcus aureus n�t �nly 
mana�e� t� �evel�� resistance t� the 
�e�ti�e �exi�anan,� a �ru� can�i�ate 
f�r �iabetic le�-ulcer infecti�ns,� but,� 
m�re ��rryin�ly,� in s�me instances als� �evel��e� cr�ss-resistance 
t� �efensin-1 �f human neutr��hils 
after bein� ex��se� t� the �e�ti�e. 
The results,� the researchers �rite 
“hi�hli�ht a �rave ��tential risk �f 
AMP thera�ies”.
Viral threats
Mean�hile,� humanity is als� 
vulnerable t� infecti�us �iseases 
that antibi�tics can’t �� anythin� 
ab�ut,� namely th�se �ri�inatin� 
fr�m viruses. Recent �utbreaks �f 
flu variants �ri�inatin� in animals 
inclu�in� bir�s an� s�ine have 
hei�htene� �ur a�areness �f the 
threat ��se� by viral z��n�ses,� 
i.e. �iseases that jum� the s�ecies 
barrier an� bec�me transmissible 
bet�een humans. This threat has 
been �ith us since the inventi�n 
�f a�riculture,� an� t��ay’s mil� 
chil�h��� infecti�ns are the embers 
�f much m�re virulent �iseases that 
are als� believe� t� have c�me fr�m 
animals an� t� have �eakene� �ver centuries �f c�-ev�luti�n �ith their 
ne� human h�sts. H��ever,� t��ay’s 
�l�bal travel habits increase the 
�an�er by makin� it ��ssible f�r a 
ne� �an�emic t� s�rea� ar�un� the 
�l�be in a sh�rt time. 
A �articular cause f�r c�ncern lies 
in the avian flu strains carryin� the 
H5 haema��lutinin,� such as H5N1. 
This strain is �i�es�rea� am�n� 
bir�s in S�utheast Asia. Fr�m 2003 
t� the en� �f 2011,� there �ere 578 
c�nfirme� cases �f humans infecte� 
�ith this strain,� an� m�re than half 
(340) �f th�se infecte� �ie�. S� far,� 
all victims �f this strain have been 
infecte� by c�ntact �ith bir�s,� s� the 
virus seems t� be unable t� s�rea� 
fr�m �ne human t� an�ther,� e.�. via 
aer�s�ls. The ��rry is that if an H5 
virus sh�ul� s�meh�� acquire the 
ability t� s�rea� bet�een humans,� 
the resultin� �an�emic c�ul� kill 
many milli�ns �f �e��le. 
As the virus hasn’t acquire� 
this ability yet,� s�me ex�erts 
��timistically assume� it mi�ht be 
intrinsically unable t� �� s�. H��ever,� 
t�� research �r�u�s have n�� 
in�e�en�ently an� �n �ifferent �aths 
arrive� at a variant H5 virus that is 
easily transmissible bet�een ferrets,� 
the mammalian m��el system �f 
ch�ice f�r such stu�ies. This fin�in� 
b�th un�ermine� �ur sense �f security 
that the H5 �an�emic mi�ht never 
ha��en an� a��e� a ne� viral threat 
t� �ur c�llective fears,� namely that 
human-transmissible H5 viruses 
c�ul� be en�ineere� an� use� as 
bi��ea��ns. 
The relevant �ublicati�ns by 
Y�shihir� Ka�a�ka’s �r�u� at the 
University �f Wisc�nsin in Ma�is�n 
an� by R�n F�uchier’s team at 
the Erasmus Me�ical Center in 
R�tter�am,� Netherlan�s,� have been 
acce�te� by Nature an� Science,� 
res�ectively,� but b�th j�urnals 
refraine� fr�m �ublishin� the full 
scientific �etails f�r fear they mi�ht 
�r�vi�e a blue�rint f�r bi��ea��ns. 
The j�urnals share� the results �ith 
the US Nati�nal Science A�vis�ry 
B�ar� f�r Bi�security (NSABB),� 
�hich rec�mmen�e� �ublicati�n 
�f the �a�ers in a re�acte� f�rm 
�ith�ut full �etails. 
In a �etaile� statement �ublishe� 
b�th in Nature an� in Science,� 
the NSABB ackn��le��e� the 
im��rtance �f the ��rk,� �hich f�r 
the first time �em�nstrate� that 
H5 viruses can easily bec�me 
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�atches �f my family t� un�erstan� 
h�� they ��rke�. I exten�e� this 
t� m�t�rbike en�ines an� seri�usly 
c�nsi�ere� �ursuin� a career as a 
bu��in� racin� en�ineer. Over the 
summer �ri�r t� enterin� university,� I 
rea� a b��k �n clinical �sych�l��y an� 
realize� the t�rments �f the brain �ere 
n�t entirely unlike th�se in the ��n�. 
This �eci�e� me t� stu�y �sych�l��y.
It �as �hen I rea� D�u�las 
H�fsta�er’s G��el,� Escher,� Bach that 
everythin� came t��ether. At the time,� 
I �as a juni�r research assistant in 
�sych�l��y in Lie�e (Bel�ium). What 
fascinate� me �as h�� a��arently 
serial th�u�hts c�ul� emer�e fr�m 
many l��er-level neur�nal 
mechanisms — �e have s� many 
neur�ns,� �hy �� �e have s� very 
fe� th�u�hts? Virtual machines in 
c�m�uter science �ffere� a meta�h�r 
f�r this ‘re�ucti�n’ bet�een c��niti�n 
an� the brain,� the c�nnecti�nist 
frame��rk s�me m��ellin� t��ls an� 
�hil�s��hy s�me f��� f�r th�u�ht �n 
the f�rms that this re�ucti�n c�ul� 
take. This c�nvince� me 
t� stu�y c�m�uter science in Bel�ium,� 
�ith �reat interest in aut�mata the�ry 
an� the c�nstraints it ��ses �n �hat 
is c�m�utable an� theref�re can be 
m��elle� an� ultimately un�erst��� as 
a mechanism. 
Ultimately,� I left f�r the US. It �as 
then the �nly c�untry �here I c�ul� 
�ursue my inter�isci�linary interests. 
My PhD in C��nitive Science at Br��n 
University �ffere� a truly re�ar�in� 
intellectual ex�erience an� ha� a bi� 
im�act �n me — �ith lectures fr�m 
Dan Kersten (c�m�utati�nal visi�n),� 
Jim An�ers�n (neural net��rk m��els),� 
Gre��ry Mur�hy (c�nce�t learnin� 
an� cate��rizati�n),� Jae���n Kim 
(�hil�s��hy �f min�),� Ulf Grenan�er 
an� Stuart Geman (statistical �attern 
rec��niti�n). Br��n �as my first 
ex�erience �f a rich envir�nment �ith a 
free fl�� �f th�u�hts bet�een A��lie� 
Mathematics,� Neur�science,� C��nitive 
Science an� Phil�s��hy. I relishe� 
these years an� have since then striven 
t� �evel�� a similar research culture.
L��kin� back,� I �as f�rtunate t� 
ex�erience the benefits �f the US 
e�ucati�nal system in my f�rmative 
years. It �as then �ell ahea� �f Eur��e 
in the ����rtunities that it �ffere� (an� 
still �ffers) f�r �enuine inter�isci�linary 
trainin�. An� �ne c�ul� easily ar�ue 
that Eur��e still has s�me �r�un�s t� 
c�ver t� bri��e bet�een �isci�lines in 
un�er�ra�uate an� �ra�uate teachin�. 
Philippe G. Schyns
Philippe Schyns is professor of visual 
neuroscience, Director of the Institute 
of Neuroscience and Psychology and 
Head of the School of Psychology at 
the University of Glasgow. He did his 
undergraduate training in Psychology 
at University of Liege (Belgium) and 
in Computer Science at University of 
Louvain-la-Neuve (Belgium). In 1992, 
he completed a PhD in Cognitive 
Science at Brown University. Following 
a post-doc with Tommaso Poggio in 
the Department of Brain and Cognitive 
Sciences at MIT he joined the faculty 
at University of Montreal. A year later, 
he moved to Glasgow University. He 
was a visiting scientist at the Advanced 
Telecommunication Research Institute 
International (Japan) in 1994 and 
1995. He leads a team researching 
the behavioural and neural aspects of 
information processing in vision. 
What turned you on to science in 
general, and to visual neuroscience 
in particular, in the first place? It 
ha��ene� in �rimary sch��l,� �n 
a Fri�ay aftern��n,� an� it �as an 
e�i�hany. We ha� a Fri�ay h�ur �urin� 
�hich �ur teacher ��ul� entertain 
us �ith st�ries,� t� kee� �ur attenti�n 
levels hi�h an� �ur misbehavin� l��. 
On this �articular �ay,� he starte� t� 
�escribe a small quiet ��n� as a casual 
�bserver ��ul� ex�erience it,� as a 
still s�rea� �f �ater �ith a fe� �ater 
lilies an� a variety �f insects s�armin� 
near the surface. With�ut transiti�n,� he 
s�itche� fr�m this �ast�ral �escri�ti�n 
t� a brutal ren�erin� �f the rich life 
an� the fi�ht f�r survival ha��enin� 
beneath still �aters. As time �as 
tickin�,� he st���e� the st�ry an� left it 
unfinishe�. He �r�mise� t� resume the 
�escri�ti�n �f nature’s battlefiel� the 
f�ll��in� Fri�ay,� but it never ha��ene�. 
I �aite� ex�ectantly f�r the st�ry t� 
finish,� literally every sin�le Fri�ay �f the 
year,� but it never �i�. 
In my turbulent hi�h-sch��l years,� I 
�as very f�rtunate that a �atient an� 
un�erstan�in� bi�l��y teacher �ave 
me a textb��k �n the bi�l��y �f the cell 
t� rea� an� re��rt �n. This �enerate� 
a �enuine fascinati�n f�r �etaile� an� 
c�m�lex mechanisms. Cl�ck��rks als� 
intereste� me an� I s�ent c�nsi�erable 
time �ismantlin� the 19th century 
Q & Atransmissible bet�een mammals. H��ever,� the NSABB als� states 
that “these scientific results als� 
re�resent a �rave c�ncern f�r �l�bal 
bi�security,� bi�safety an� �ublic 
health”. The analysis c�nclu�es that 
“because the NSABB f�un� that 
there �as si�nificant ��tential 
f�r harm in fully �ublishin� these 
results an� that the harm excee�e� 
the benefits �f the �ublicati�n,� �e 
theref�re rec�mmen�e� that the 
��rk n�t be fully c�mmunicate� in 
an ��en f�rum”. 
B�th �r�u� lea�ers have �r�teste� 
a�ainst the �ecisi�n,� claimin� that 
full �ublicati�n �f their results ��ul� 
n�t create a��iti�nal risks. Ka�a�ka 
�rites in a c�mmentary in Nature: 
“I believe that the benefits �f these 
stu�ies — the kn��le��e that H5 
HA-��ssessin� viruses ��se a risk 
an� the ability t� m�nit�r them 
an� �evel�� c�untermeasures — 
�ut�ei�h the risk.” 
Other ex�erts are n�t s� sure 
that there is an imme�iate benefit 
t� be �aine� fr�m �i�es�rea� 
sharin� �f the �etails,� as there is n� 
infrastructure in �lace that ��ul� 
enable anyb��y t� m�nit�r f�r the 
emer�ence �f human transmissible 
H5 viruses in nature. “Surveillance 
�f influenza in animals is sl�� an� 
�atchy at best,� an� the f�ll��-u� 
sequencin� �f sam�les m�re s�,�” 
bem�ans an e�it�rial in Nature. 
Even if a �an�er�us H5 virus �ith 
mutati�ns similar t� the �nes 
create� in the lab �as �icke� u� 
by m�nit�rin� eff�rts early �n,� it is 
n�t clear that this ��ul� im�r�ve 
�ur chances. “At �resent,� such 
a�vance kn��le��e ��ul� make 
little �ifference t� the ��rl�’s 
limite� abilities t� manufacture an� 
�istribute vaccines,�” the e�it�rial 
c�nclu�es. 
Given the hi�hly c�ntr�versial 
�ebate �n these �r�blems,� flu 
researchers have a�ree� a 60-�ay 
m�rat�rium �n this kin� �f research,� 
t� all�� scientists an� ��liticians 
time t� fin� safe �ays �f han�lin� 
such �an�er�us inf�rmati�n. They 
may als� �ant t� im�r�ve their 
c�ntin�ency �lans f�r the case that 
a human-transmissible H5 virus,� be 
it fr�m nature �r fr�m the lab,� ��es 
start a �an�emic. 
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